Accurate Education – Understanding Postbiotics: A Physician Guide

The 4-Domain Approach to Chronic Pain:

Understanding Postbiotics: A Physician Guide

You may have heard of probiotics (the “good bacteria” in yogurt and supplements) and prebiotics (the fiber that feeds those good bacteria). Postbiotics are the third member of this gut health family—and they may be the easiest to understand.

The 4-D protocols are not intended to replace conventional management of chronic pain, but to complement it.

See:  

The 4-Domain Approach to Chronic Pain

Gut Health

   Synbiotics

• Synbiotics for Chronic Pain: A Patient Guide
• Synbiotics for Chronic Pain: A Physician Guide
• Synbiotics – Evidence for Efficacy in Chronic Pain
• Symbiotics – Food-Based Synbiotics for Chronic Pain: A Patient Guide
• Synbiotics – Evidence-Based Formulations
• Synergistic Protocols – Synbiotics + Nutraceuticals

   Probiotics

• Understanding Postbiotics: A Patient Guide
• Understanding Postbiotics: A Physician Guide

 

 

 

 

 

Key to Links:

• Grey text – handout
• Red text – another page on this website
• Blue text – Journal publication

Definitions and Terms Related to Pain

 

Postbiotics Addendum to Synbiotics for Chronic Pain: 

Understanding Postbiotics: A Physician Guide

1. DEFINITION AND CLASSIFICATION

Postbiotics are defined by the International Scientific Association for Probiotics and Prebiotics (ISAPP) as “a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host.”

This definition encompasses:[1][2]

   Category 1: Inactivated Whole Cells (Paraprobiotics)

• Heat-killed bacteria (most common)
• UV-inactivated bacteria
• Sonicated bacterial preparations (bacteria that have been disrupted by sound waves)

   Category 2: Cell Components

• Cell wall fragments (peptidoglycan, lipoteichoic acid)
• Exopolysaccharides (EPS)
• Surface proteins and S-layer proteins

   Category 3: Metabolites

• Short-chain fatty acids (SCFAs): butyrate, propionate, acetate
• Organic acids (lactic acid, acetic acid)
• Bacteriocins and antimicrobial peptides
• Vitamins (B-complex, K)
• Enzymes
• Tryptophan metabolites (indole derivatives)
• Peptides and amino acids

—

2. RATIONALE FOR POSTBIOTIC INTEGRATION

Advantages Over Live Probiotics:[3][4][5][6][7]

Parameter	Probiotics	Postbiotics	Clinical Implication
Viability requirement	Must remain alive	No viability needed	Superior stability
Storage	Often requires refrigeration	Shelf-stable	Better compliance
Safety in immunocompromised	Risk of translocation/infection	No infection risk	Broader applicability
Dosing consistency	Variable CFU survival	Standardized bioactive content	Reproducible effects
Antibiotic co-administration	Killed by antibiotics	Unaffected	Can use concurrently
Onset of action	Requires colonization	Direct bioactivity	Potentially faster

 

Comparable Efficacy Evidence:

A meta-analysis comparing heat-killed probiotics to live probiotics in IBD models found no statistically significant difference in efficacy for colon length, disease activity index, or histological score, supporting the therapeutic equivalence of postbiotics.[8]

—

3. POSTBIOTIC IMPACT ON THE FOUR DOMAINS

   3.1 Systemic Inflammation (HIGH Quality Evidence):

   Sodium Butyrate Clinical Trials:

• Ulcerative colitis RCT (2024): 600 mg/day sodium butyrate for 12 weeks significantly decreased fecal calprotectin (-133.82 vs. +51.58 placebo, P0.001) and hs-CRP (-0.36 vs. +0.48 placebo, P0.001)[9]
• Microencapsulated sodium butyrate RCT (2025): 600 mg/day for 8 weeks achieved clinical improvement in 51% (P=0.005), clinical remission in 31.4% (P=0.004), and biochemical remission in 42.2% (P=0.009) of UC patients[10]
• Metabolic syndrome trial: 4 g/day sodium butyrate for 4 weeks decreased oxLDL-induced trained immunity and reduced TNF-α and IL-6 responses in monocytes[11]

   Mechanisms:[12][13][14]

• Inhibits NF-κB phosphorylation and NLRP3 inflammasome activation
• Activates GPR109A receptor signaling
• Reduces TNF-α, IL-1β, IL-6 secretion
• Inhibits AKT signaling pathway
• Reduces mitochondrial ROS-mediated macrophage pyroptosis

3.2 Neuroinflammation (MODERATE Quality Evidence):

   Mechanisms:[15][16][17][18]

• Butyrate crosses the blood-brain barrier via monocarboxylate transporters
• Acts as HDAC inhibitor in CNS, modulating gene expression
• Reduces microglial activation and neuroinflammation
• Modulates neurotransmitter synthesis and signaling
• Regulates circadian clock gene expression (CRY1, CRY2, PER1, BMAL1)[9]

   Clinical Evidence:

• Sodium butyrate supplementation significantly upregulated circadian clock genes and improved sleep quality in UC patients (PSQI score: -2.94 vs. +1.16 placebo, P0.001)[9]
• Tributyrin (butyrate prodrug) demonstrated target engagement in Parkinson’s disease with systemic anti-inflammatory effects and improvements in cognitive and motor features[19]
• Gut microbiota depletion prevented nerve injury-induced mechanical allodynia and thermal hyperalgesia; recolonization restored pain sensitivity[20]

3.3 Oxidative Stress (HIGH Quality Evidence):

   Mechanisms:[12][21][22]

• Activates Nrf2/HO-1 antioxidant pathway
• Upregulates NQO1 expression
• Reduces malondialdehyde (MDA) accumulation
• Restores glutathione (GSH) activity
• Inhibits myeloperoxidase (MPO) activity
• Promotes mitophagy via Pink1/Parkin pathway

   Evidence:

• Sodium butyrate reduced abdominal ROS chemiluminescence signaling in colitis models[12]
• L. rhamnosus 1.0320 postbiotics upregulated Nrf2/ARE pathway proteins (NQO1, Nrf2, HO-1) and reduced oxidative stress markers[21][22]
• Postbiotic administration increased anti-inflammatory metabolites including baicalein and diosmetin with known antioxidant properties[23]

3.4 Mitochondrial Dysfunction (MODERATE Quality Evidence):

   Mechanisms:[12][14][19]

• Butyrate serves as direct energy substrate for colonocytes
• Promotes mitophagy via Pink1/Parkin activation, removing dysfunctional mitochondria
• Inhibits mitochondrial ROS-mediated pyroptosis
• Enhances mitochondrial membrane potential
• Modulates mitochondrial proton transport via adenine nucleotide translocase (ANT)

   Evidence:

• Sodium butyrate promoted mitophagy via Pink1/Parkin pathway activation in colitis models[12]
• Tributyrin demonstrated organ-specific changes in butyrate availability via PET imaging, confirming CNS target engagement[19]
• Butyrate alleviates colitis by inhibiting mitochondrial ROS-mediated macrophage pyroptosis[14]

—

4. POSTBIOTIC IMPACT ON PAIN SENSITIZATION

   4.1 Peripheral Sensitization (MODERATE Quality Evidence):

   Direct Evidence:

• Exopolysaccharide (EPS) from Lactobacillus BGCG11 produced significant dose-dependent reduction in mechanical hyperalgesia in carrageenan-induced inflammatory pain model, with decreased IL-1β and TNF-α mRNA expression in paw tissue[24]
• FMT from healthy donors to CCI rats downregulated pain-related proteins TRPM8, Nav1.8, Nav1.7, and TRPA1 in dorsal root ganglia[25]
• Probiotic-derived metabolites modulate TRPV1, cannabinoid (CB1, CB2), opioid (mu, kappa), and serotonin (5-HT) receptors on nociceptors[26]

   Mechanisms:[15][25]

• Gut microbiota-derived mediators directly regulate primary nociceptor excitability
• SCFAs act on GPR41/GPR43 receptors on sensory neurons
• Restoration of blood-nerve barrier integrity
• Reduction of peripheral pro-inflammatory cytokines

   4.2 Central Sensitization (MODERATE Quality Evidence):

   Direct Evidence:

• Gut microbiota depletion prevented nerve injury-induced mechanical allodynia and thermal hyperalgesia; upon recolonization, pain relapsed[20]
• FMT (Fecal Microbiota Transplantation) from CCI rats to healthy rats induced pain-like hypersensitivity, mimicking nerve injury effects[25]
• Probiotic treatment inhibited nerve injury-induced TNF-α expression in the spinal cord and pain sensitization[27]

   Mechanisms:[15][17][25]

• SCFAs cross BBB and modulate microglial activation
• Regulation of spinal cord inflammatory mediators
• Modulation of descending pain inhibitory pathways
• FMT from healthy donors increased anti-inflammatory markers (TGF-β, IL-10) while decreasing neuroinflammatory markers (IBA1, TNF-α, IL-1β)[25]

—

5. SPECIFIC POSTBIOTIC COMPOUNDS FOR CHRONIC PAIN

   5.1 Sodium Butyrate (Primary Postbiotic Recommendation)

   Pain-Specific Evidence:

Pain Model	Dose	Effect	Mechanism	References
Neuropathic (CCI)	100-400 mg/kg (preclinical)	Significant reduction in mechanical allodynia and thermal hyperalgesia	PPAR-α/γ activation, HDAC inhibition	[1], [2]
Fibromyalgia	100 mg/kg (preclinical)	Attenuated mechanical allodynia, cold hypersensitivity, anxiety, cognitive impairment	↑ IL-4, ↑ TGF-β1, ↓ NF-κB, ↑ synaptophysin	[3]
Rheumatoid Arthritis	Preclinical doses	Reduced inflammation	HDAC2/HDAC8 inhibition, Treg/Th17 balance	[4]
Visceral Pain	Variable	Modulates visceral sensitivity	GPR109A activation, barrier enhancement	[5]

 

Human Dosing Protocols:

Indication	Dose	Duration	Formulation	Evidence Level	References
Inflammatory conditions	600 mg/day	8-12 weeks	Microencapsulated (MSB®)	RCT	[1], [2]
Metabolic syndrome	4 g/day	4 weeks	Standard sodium butyrate	RCT	[3]
General supplementation	500-2000 mg/day	8+ weeks	Various	Extrapolated	[4], [5]
Weight/metabolic	1875 mg/day	12 weeks	Standard	RCT	[6]

 

Formulation Considerations:

• Microencapsulated sodium butyrate (MSB®): Colon-targeted delivery, improved efficacy, better tolerability[10][33]
• Standard sodium butyrate: Effective but may have unpleasant taste/odor; enteric coating recommended
• Calcium/magnesium butyrate: Alternative salts with similar efficacy

   5.2 Tributyrin (Butyrate Prodrug)

   Advantages Over Sodium Butyrate:[36][19][37][38]

• Neutral triglyceride form (naturally present in butter)
• 3-4 fold more potent than sodium butyrate on molar basis
• Better pharmacokinetics: slower release, higher plasma/brain concentrations
• Improved palatability
• Delivers butyrate to both small intestine and colon

   Clinical Evidence:

• Parkinson’s disease trial (2026): 500 mg TID (1500 mg/day) for 30 days demonstrated target engagement via PET imaging, systemic anti-inflammatory effects, and improvements in cognitive and motor features[19]

      Dosing:

• 500 mg three times daily (1500 mg/day) based on Parkinson’s trial[19]
• Microencapsulated forms may enhance colonic delivery[37]

   5.3 Heat-Killed Bacterial Preparations

   Evidence for Equivalence to Live Probiotics:

Strain	Comparison	Finding	References
B. longum B8762	Viable vs. heat-killed	Similar efficacy in reducing intestinal inflammation, modulating microbiota diversity, and altering fecal metabolome	[1]
L. fermentum CECT5716	Viable vs. heat-killed	Both reduced IL-1β, TNF-α, iNOS expression; viability not essential for anti-inflammatory effect	[2]
L. rhamnosus GG	Live vs. heat-killed	Both decreased LPS-induced pro-inflammatory mediators and increased anti-inflammatory mediators	[3]
L. argentoratensis BBLB001	Heat-killed	Reduced IL-8 secretion, enhanced cell adhesion factors, alleviated DSS-induced colitis	[4]

Clinical Application:

• Heat-killed preparations can be used in patients with contraindications to live probiotics
• Particularly valuable for immunocompromised patients, those on antibiotics, or critically ill
• Dosing typically equivalent to live probiotic CFU counts

 

5.4 Exopolysaccharides (EPS)

   Direct Analgesic Evidence:

A landmark study demonstrated that EPS from Lactobacillus BGCG11 reduced inflammatory hyperalgesia in rats in a dose-dependent manner, with decreased IL-1β and TNF-α expression. This represents the first reported antihyperalgesic effect of bacterial EPS.[24]

   Anti-Inflammatory Mechanisms:[43][44][45][46][47]

• TLR4-mediated induction of anti-inflammatory M2 macrophages
• IDO expression induction via kynurenine/aryl hydrocarbon receptor pathway
• Inhibition of TNF-α, IL-6, IL-1β secretion
• Stimulation of anti-inflammatory IL-10
• Does not induce inflammatory cytokines (unlike LPS, despite both being TLR4 agonists)[43]

   Structure-Activity Relationship:

• EPS with high galactose content shows enhanced anti-inflammatory activity[45]
• EPS with high fructose content demonstrates excellent in vivo anti-inflammatory activity[44]
• Molecular weight and monosaccharide composition influence efficacy

   5.5 Tryptophan Metabolites (Indole Derivatives)

   Key Compounds:[48][49]

• Indole-3-lactic acid (ILA): More prevalent in Bifidobacterium CFS
• 3-Indoleacrylic acid (IAA): More concentrated in Lactobacillus CFS
• Kynurenic acid: Elevated by JK5G postbiotics in cancer pain trial[50]

   Mechanisms:

• Activate aryl hydrocarbon receptor (AhR) for immune modulation
• Regulate intestinal barrier function
• Modulate neuroinflammation via gut-brain axis

—

6. INTEGRATION WITH THE 4-D NUTRACEUTICAL PROTOCOL

6.1 Synergistic Stacks

Stack A: Inflammation-Dominant (Enhanced)

Component	Dose	Timing	Synergy Mechanism
Sodium butyrate (microencapsulated)	300-600 mg	Morning with food	NF-κB inhibition, HDAC inhibition
Synbiotic	Full protocol dose	Morning with food	Endogenous SCFA production
Omega-3 (EPA/DHA)	2-3 g	With meals	SPM production, membrane effects
Curcumin	500-1000 mg	With meals	Complementary NF-κB inhibition

Rationale: Sodium butyrate provides immediate SCFA delivery while synbiotics support endogenous production. Combined with omega-3 and curcumin, this creates multi-pathway NF-κB inhibition and enhanced anti-inflammatory signaling.

 

Stack B: Neuroinflammation-Dominant (Enhanced)

Component	Dose	Timing	Synergy Mechanism
Tributyrin	500 mg TID	With meals	BBB penetration, HDAC inhibition in CNS
Synbiotic	Full protocol dose	Morning	Gut-brain axis modulation
PEA	600 mg BID	Morning/evening	Neuroinflammation via PPAR-α
Melatonin	3-5 mg	Bedtime	Circadian regulation, neuroinflammation

Rationale: Tributyrin’s superior pharmacokinetics allow better CNS penetration than sodium butyrate. Combined with PEA’s PPAR-α activation and melatonin’s circadian/anti-inflammatory effects, this targets central sensitization mechanisms.

 

Stack C: Oxidative Stress-Dominant (Enhanced)

Component	Dose	Timing	Synergy Mechanism
Sodium butyrate	300-600 mg	Morning	Nrf2/HO-1 activation
Synbiotic	Full protocol dose	Morning	Endogenous antioxidant support
NAC	600-1200 mg	Morning/evening	Glutathione precursor
Alpha-lipoic acid	300-600 mg	Morning	Mitochondrial antioxidant
Sulforaphane	10-30 mg	Morning	Nrf2 activation

Rationale: Butyrate activates Nrf2/HO-1 pathway, synergizing with sulforaphane’s Nrf2 activation. NAC provides glutathione substrate while ALA offers mitochondrial-specific antioxidant protection.

 

Stack D: Mitochondrial Dysfunction-Dominant (Enhanced)

Component	Dose	Timing	Synergy Mechanism
Sodium butyrate	300-600 mg	Morning	Mitophagy promotion, energy substrate
Synbiotic	Full protocol dose	Morning	SCFA production for colonocyte energy
CoQ10	200-400 mg	Morning with fat	Electron transport chain support
Acetyl-L-carnitine	1000-2000 mg	Morning	Fatty acid transport, documented synergy
Nicotinamide riboside	250-500 mg	Morning	NAD+ precursor
D-Ribose	5 g	Morning	ATP substrate

Rationale: Butyrate promotes mitophagy (Pink1/Parkin pathway) while serving as energy substrate. The documented synergy between L-carnitine and synbiotics (↓ IL-6 34%, ↓ TNF-α 19%, ↓ MDA 22%) supports this combination.[51]

 

6.2 Phased Implementation Protocol

   Phase 1: Foundation (Weeks 1-2)

• Introduce synbiotic at half dose
• Add sodium butyrate 300 mg/day (or tributyrin 500 mg/day)
• Monitor for GI tolerance

   Phase 2: Optimization (Weeks 3-4)

• Increase synbiotic to full dose
• Increase sodium butyrate to 600 mg/day (or tributyrin 500 mg BID)
• Add foundational nutraceuticals (omega-3, vitamin D, magnesium)

  Phase 3: Domain-Specific Enhancement (Weeks 5-8)

• Add domain-specific nutraceuticals based on patient’s dominant pathophysiology
• Consider tributyrin for neuroinflammation-dominant presentations
• Consider higher butyrate doses (up to 2000 mg/day) for high inflammatory burden

  Phase 4: Maintenance (Weeks 9+)

• Optimize doses based on response
• Consider cycling between sodium butyrate and tributyrin
• Assess inflammatory markers (CRP, ESR) at 8-12 weeks

—

7. PRODUCT RECOMMENDATIONS

7.1 Sodium Butyrate Products

Product Category	Characteristics	Recommended For	Approximate Cost
Microencapsulated (MSB® technology)	Colon-targeted, evidence-based	UC, IBD, inflammatory conditions	$30-50/month
Enteric-coated capsules	Delayed release, reduced odor	General supplementation	$20-40/month
Calcium/magnesium butyrate	Alternative salts, better tolerated	Sodium-sensitive patients	$25-45/month
Butyrate + prebiotic combinations	Synbiotic effect	Comprehensive gut support	$35-55/month

Quality Criteria:

• Third-party tested (USP, NSF, ConsumerLab)
• Enteric coating or microencapsulation for colonic delivery
• Standardized butyrate content
• Free from unnecessary additives

7.2 Tributyrin Products

Product Type	Dose per Serving	Notes	Approximate Cost
Tributyrin capsules	250-500 mg	Most common form	$30-50/month
Microencapsulated tributyrin	Variable	Enhanced colonic delivery	$40-60/month
Tributyrin + omega-3 combinations	Variable	Synergistic formulation	$45-65/month

 

7.3 Heat-Killed Probiotic Products

Product Type	Key Strains	Indication	References
*Heat-killed L. rhamnosus***	LGG or similar	General inflammation, mitophagy	[1], [2]
*Heat-killed B. longum***	B8762 or similar	IBD, gut inflammation	[3]
Heat-killed multi-strain	Various	Broad-spectrum postbiotic	[4]
JK5G postbiotics	Inactivated Lactobacillus + metabolites	Cancer-related pain (emerging)	[5]

—

8. SAFETY AND CONTRAINDICATIONS

8.1 Sodium Butyrate Safety

   Generally Well-Tolerated:[53][33][34][54]

• Most common side effects: GI discomfort, bloating, flatulence (usually transient)
• Unpleasant taste/odor with uncoated preparations

   Cautions:[53][55]

• High doses (>2.5 g/kg in animal models): Can induce reversible hypothermia through transient mitochondrial proton leak in brain neurons[55]
• Insufficient evidence: Long-term safety data in humans limited; most trials 4-12 weeks
• Dietary approach may be safer: Dietary patterns rich in fiber that promote endogenous butyrate production may be preferable for long-term use[53]

Contraindications:

• No absolute contraindications established
• Use caution in patients with severe hepatic impairment (first-pass metabolism)
• Consider lower doses in elderly or debilitated patients

8.2 Tributyrin Safety

   Generally Safe:[19][38]

• Naturally present in butter and dairy products
• Parkinson’s trial demonstrated reassuring safety profile with high adherence[19]
• No serious adverse events reported at 1500 mg/day for 30 days

   Cautions:

• May increase inflammatory markers in healthy colon tissue at high doses (preclinical)[36]
• Limited long-term human safety data

8.3 Heat-Killed Preparations Safety

   Excellent Safety Profile:[3][4][7]

• No risk of bacterial translocation or infection
• Safe for immunocompromised patients
• Safe for concurrent antibiotic use
• No viability concerns

—

9. MONITORING AND ASSESSMENT

   9.1 Baseline Assessment

• Inflammatory markers: CRP, ESR, fecal calprotectin (if GI symptoms)
• Pain scores: VAS, validated pain questionnaires
• Quality of life measures
• GI symptom assessment

   9.2 Follow-Up Assessment (8-12 Weeks)

• Repeat inflammatory markers
• Pain score reassessment
• Adverse effect monitoring
• Compliance assessment

   9.3 Response Indicators

   Positive Response:

• ≥30% reduction in pain scores
• Reduction in CRP/ESR
• Improved sleep quality
• Reduced medication requirements

   Consider Dose Adjustment If:

• Inadequate response at 8 weeks
• GI intolerance limiting compliance
• Inflammatory markers unchanged

—

10. CLINICAL DECISION ALGORITHM

   Step 1: Assess Patient Suitability

• Contraindications to live probiotics? → Consider postbiotics alone
• On antibiotics? → Postbiotics preferred during treatment
• Immunocompromised? → Postbiotics only (no live bacteria)
• Standard patient? → Synbiotic + postbiotic combination

   Step 2: Select Postbiotic Based on Dominant Domain

• Systemic inflammation dominant → Microencapsulated sodium butyrate 600 mg/day
• Neuroinflammation dominant → Tributyrin 500 mg TID
• Oxidative stress dominant → Sodium butyrate + Nrf2 activators
• Mitochondrial dysfunction dominant → Sodium butyrate + mitochondrial support stack

   Step 3: Integrate with Protocol

• Add postbiotic to existing synbiotic regimen
• Follow phased implementation
• Monitor response at 8-12 weeks

   Step 4: Optimize

• Adjust doses based on response
• Consider switching between sodium butyrate and tributyrin
• Add heat-killed preparations if live probiotics contraindicated

—

11. KEY TAKEAWAYS

1. Postbiotics are the “third pillar” of the biotic trilogy, offering comparable efficacy to probiotics with superior stability and safety

2. Sodium butyrate is the most evidence-supported postbiotic for chronic pain, with RCT evidence for anti-inflammatory effects and preclinical evidence for direct analgesic effects

3. Tributyrin offers pharmacokinetic advantages (better CNS penetration) and may be preferred for neuroinflammation-dominant presentations

4. Heat-killed preparations provide a safe alternative for patients with contraindications to live probiotics

5. Exopolysaccharides represent an emerging postbiotic class with direct antihyperalgesic evidence

6. Integration with synbiotics creates a comprehensive approach: synbiotics support endogenous SCFA production while postbiotics provide immediate bioactive delivery

7. Dosing: Sodium butyrate 300-600 mg/day (up to 2000 mg/day for high inflammatory burden); Tributyrin 500 mg TID

8. Duration: Minimum 8 weeks for inflammatory marker changes; 10-12 weeks for pain outcomes

—

SUMMARY

This comprehensive addendum integrates postbiotics into the 4-D chronic pain protocol based on the current evidence. The strongest evidence supports sodium butyrate as the primary postbiotic, with RCTs demonstrating significant reductions in inflammatory markers (hs-CRP, calprotectin) and improvements in clinical outcomes in ulcerative colitis.[9][10] Preclinical studies provide direct evidence for analgesic effects in neuropathic pain and fibromyalgia models.[28][29][30]

Tributyrin emerges as a promising alternative with superior pharmacokinetics—it is 3-4 fold more potent than sodium butyrate on a molar basis and achieves better plasma and brain concentrations.[19][38] The recent Parkinson’s disease trial demonstrating target engagement and clinical improvements supports its use for neuroinflammation-dominant presentations.[19]

The exopolysaccharide (EPS) evidence is particularly noteworthy for your protocol, as this represents the first documented direct antihyperalgesic effect of a bacterial postbiotic component, with dose-dependent reduction in inflammatory hyperalgesia.[24]

The documented synergy between L-carnitine and synbiotics (↓ IL-6 34%, ↓ TNF-α 19%, ↓ MDA 22%, ↓ LPS 10%) provides a model for how postbiotics can enhance the efficacy of the existing nutraceutical stacks.[51]

References

1. The International Scientific Association of Probiotics and Prebiotics (ISAPP) Consensus Statement on the Definition and Scope of Postbiotics. Salminen S, Collado MC, Endo A, et al. Nature Reviews. Gastroenterology & Hepatology. 2021;18(9):649-667. doi:10.1038/s41575-021-00440-6.
2. Frequently Asked Questions About the ISAPP Postbiotic Definition. Vinderola G, Sanders ME, Cunningham M, Hill C. Frontiers in Microbiology. 2023;14:1324565. doi:10.3389/fmicb.2023.1324565.
3. The Clinical Evidence for Postbiotics as Microbial Therapeutics. Mosca A, Abreu Y Abreu AT, Gwee KA, et al. Gut Microbes. 2022 Jan-Dec;14(1):2117508. doi:10.1080/19490976.2022.2117508.
4. Postbiotics and Extracellular Vesicles: Mechanisms of Action and Clinical Promise in Respiratory Infections and Inflammation. Fadaee M, Mahrooghi D, Lahouty M, Oskouei SA, Nezhadi J. Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases. 2025;:105837. doi:10.1016/j.meegid.2025.105837.
5. Postbiotics as the New Frontier in Food and Pharmaceutical Research. Sabahi S, Homayouni Rad A, Aghebati-Maleki L, et al. Critical Reviews in Food Science and Nutrition. 2023;63(26):8375-8402. doi:10.1080/10408398.2022.2056727.
6. An Integrated Engineering Approach to Creating Health-Modulating Postbiotics. Chikindas ML, Roopchand DE, Tiwari SK, et al. Molecular Nutrition & Food Research. 2025;:e70326. doi:10.1002/mnfr.70326.
7. Postbiotics at the Interface of Microbial Biotechnology and Therapeutics: Industrial Production, Functional Mechanisms, and Clinical Potentials. Balakrishna K, Naveena G, Kingston JJ. Archives of Microbiology. 2026;208(2):123. doi:10.1007/s00203-025-04701-9.
8. Are Heat-Killed Probiotics More Effective Than Live Ones on Colon Length Shortness, Disease Activity Index, and the Histological Score of an Inflammatory Bowel Disease-Induced Murine Model? A Meta-Analysis. Poaty Ditengou JIC, Ahn SI, Chae B, Choi NJ. Journal of Applied Microbiology. 2023;134(3):lxad008. doi:10.1093/jambio/lxad008.
9. Effects of Short-Chain Fatty Acid-Butyrate Supplementation on Expression of Circadian-Clock Genes, Sleep Quality, and Inflammation in Patients With Active Ulcerative Colitis: A Double-Blind Randomized Controlled Trial. Firoozi D, Masoumi SJ, Mohammad-Kazem Hosseini Asl S, et al. Lipids in Health and Disease. 2024;23(1):216. doi:10.1186/s12944-024-02203-z.
10. Efficacy of Microencapsulated Sodium Butyrate as Add-on Therapy in Inducing Remission in Patients With Mild-to-Moderate Ulcerative Colitis: Results From a Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study. Karłowicz K, Lewandowski K, Kaniewska MA, et al. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 2025;31:e948912. doi:10.12659/MSM.948912.
11. Effects of Oral Butyrate Supplementation on Inflammatory Potential of Circulating Peripheral Blood Mononuclear Cells in Healthy and Obese Males. Cleophas MCP, Ratter JM, Bekkering S, et al. Scientific Reports. 2019;9(1):775. doi:10.1038/s41598-018-37246-7.
12. Sodium Butyrate Inhibits Oxidative Stress and NF-κB/NLRP3 Activation in Dextran Sulfate Sodium Salt-Induced Colitis in Mice With Involvement of the Nrf2 Signaling Pathway and Mitophagy. Bian Z, Zhang Q, Qin Y, et al. Digestive Diseases and Sciences. 2023;68(7):2981-2996. doi:10.1007/s10620-023-07845-0.
13. Sodium Butyrate Inhibits Inflammation and Maintains Epithelium Barrier Integrity in a TNBS-induced Inflammatory Bowel Disease Mice Model. Chen G, Ran X, Li B, et al. EBioMedicine. 2018;30:317-325. doi:10.1016/j.ebiom.2018.03.030.
14. Sodium Butyrate Alleviates Colitis by Inhibiting Mitochondrial ROS Mediated Macrophage Pyroptosis. Fan G, Liu Y, Tao L, et al. Biochimica Et Biophysica Acta. Molecular Basis of Disease. 2025;1871(5):167756. doi:10.1016/j.bbadis.2025.167756.
15. Pain Regulation by Gut Microbiota: Molecular Mechanisms and Therapeutic Potential. Guo R, Chen LH, Xing C, Liu T. British Journal of Anaesthesia. 2019;123(5):637-654. doi:10.1016/j.bja.2019.07.026.
16. Role of Gut Microbiota in Neuropathy and Neuropathic Pain States: A Systematic Preclinical Review. Pane K, Boccella S, Guida F, et al. Neurobiology of Disease. 2022;170:105773. doi:10.1016/j.nbd.2022.105773.
17. Advances in the Study of Intestinal Microbiota and Neuropathic Pain. Jiang Y, Xu H, Zhang W, et al. Frontiers in Bioscience (Landmark Edition). 2025;30(11):43051. doi:10.31083/FBL43051.
18. Therapeutic Potential of Sodium Butyrate in Neurological and Psychiatric Disorders. Rahmani D, Chodari L, Kakallahpour M, Niknam Z. Molecular Neurobiology. 2025;63(1):90. doi:10.1007/s12035-025-05428-w.
19. Dietary Tributyrin Supplementation in Parkinson’s Disease: An Open-Label Target Engagement Study. Bohnen JLB, Roytman S, Wigstrom TP, et al. Neurotherapeutics : The Journal of the American Society for Experimental NeuroTherapeutics. 2026;23(1):e00791. doi:10.1016/j.neurot.2025.e00791.
20. Gut Microbiota Depletion by Antibiotics Ameliorates Somatic Neuropathic Pain Induced by Nerve Injury, Chemotherapy, and Diabetes in Mice. Ma P, Mo R, Liao H, et al. Journal of Neuroinflammation. 2022;19(1):169. doi:10.1186/s12974-022-02523-w.
21. Lactobacillus Rhamnosus 1.0320 Postbiotics Ameliorate Dextran Sodium Sulfate-Induced Colonic Inflammation and Oxidative Stress by Regulating the Intestinal Barrier and Gut Microbiota. Zhang J, Duan X, Chen X, et al. Journal of Agricultural and Food Chemistry. 2024;72(45):25078-25093. doi:10.1021/acs.jafc.4c06303.
22. Probiotics and Postbiotics Produced by Lacticaseibacillus Rhamnosus 1.0320 Isolated From Traditional Fermented Dairy Products Alleviate DSS-Induced Colitis by Modulating the Gut Microbiota and Intestinal Metabolism. Zhang J, Tan Z, Tian Z, et al. Journal of Agricultural and Food Chemistry. 2025;. doi:10.1021/acs.jafc.5c04623.
23. Postbiotic Administration Ameliorates Colitis and Inflammation in Rats Possibly Through Gut Microbiota Modulation. Feng C, Peng C, Zhang W, et al. Journal of Agricultural and Food Chemistry. 2024;. doi:10.1021/acs.jafc.3c03901.
24. Exopolysaccharide Produced by Probiotic Strain BGCG11 Reduces Inflammatory Hyperalgesia in Rats. Dinić M, Pecikoza U, Djokić J, et al. Frontiers in Pharmacology. 2018;9:1. doi:10.3389/fphar.2018.00001.
25. Fecal Microbiota Transplantation Attenuates Neuropathic Pain in Rats via Gut Microbiota-Mediated Immunomodulation of Ion Channels and Nociceptors. Allani M, Nath G, Juyal G, Chandra Joshi M, Tiwari V. Microbial Pathogenesis. 2026;:108275. doi:10.1016/j.micpath.2026.108275.
26. Tolerogenic Probiotics and Gut-Brain Axis: Targeting Pain Receptors in Neuroimmune Disorders. Ahmadi-Khorram M, Hatami A, Forouzanfar F, Afshari A, Esmaeili SA. Nutritional Neuroscience. 2025;:1-21. doi:10.1080/1028415X.2025.2567415.
27. Nerve Injury-Induced Gut Dysbiosis Contributes to Spinal Cord TNF-α Expression and Nociceptive Sensitization. Lee J, Lee G, Ko G, Joong Lee S. Brain, Behavior, and Immunity. 2023;110:155-161. doi:10.1016/j.bbi.2023.03.005.
28. Sodium Butyrate and Its Synthetic Amide Derivative Modulate Nociceptive Behaviors in Mice. Russo R, De Caro C, Avagliano C, et al. Pharmacological Research. 2016;103:279-91. doi:10.1016/j.phrs.2015.11.026.
29. Attenuation of Neuropathic Pain by Sodium Butyrate in an Experimental Model of Chronic Constriction Injury in Rats. Kukkar A, Singh N, Jaggi AS. Journal of the Formosan Medical Association = Taiwan Yi Zhi. 2014;113(12):921-8. doi:10.1016/j.jfma.2013.05.013.
30. The Immunomodulatory Effects of Ethosuximide and Sodium Butyrate on Experimentally Induced Fibromyalgia: The Interaction Between IL-4, Synaptophysin, and TGF-β1/NF-κB Signaling. Abd Elmaaboud MA, Awad MM, El-Shaer RAA, Kabel AM. International Immunopharmacology. 2023;118:110061. doi:10.1016/j.intimp.2023.110061.
31. Attenuation of Rheumatoid Inflammation by Sodium Butyrate Through Reciprocal Targeting of HDAC2 in Osteoclasts and HDAC8 in T Cells. Kim DS, Kwon JE, Lee SH, et al. Frontiers in Immunology. 2018;9:1525. doi:10.3389/fimmu.2018.01525.
32. Potential Beneficial Effects of Butyrate in Intestinal and Extraintestinal Diseases. Canani RB, Costanzo MD, Leone L, et al. World Journal of Gastroenterology. 2011;17(12):1519-28. doi:10.3748/wjg.v17.i12. 1519.
33. Use of Sodium Butyrate and Its Microencapsulated Forms in Intestinal Diseases-Current Clinical Approach. Caban M, Pikus E, Czarnecka-Chrebelska K, et al. Digestive Diseases and Sciences. 2025;:10.1007/s10620-025-09536-4. doi:10.1007/s10620-025-09536-4.
34. Butyrate’s Role in Human Health and the Current Progress Towards Its Clinical Application to Treat Gastrointestinal Disease. Hodgkinson K, El Abbar F, Dobranowski P, et al. Clinical Nutrition (Edinburgh, Scotland). 2023;42(2):61-75. doi:10.1016/j.clnu.2022.10.024.
35. Targeting Weight Loss and Blood Glucose Control With Oral Sodium Butyrate in Overweight/Obese Adults With and Without Type 2 Diabetes: A Proof-of-Concept Randomized Controlled Trial. Testa R, Vitale M, Giosuè A, et al. Clinical Nutrition (Edinburgh, Scotland). 2026;60:106624. doi:10.1016/j.clnu.2026.106624.
36. Oral Tributyrin Treatment Affects Short-Chain Fatty Acid Transport, Mucosal Health, and Microbiome in a Mouse Model of Inflammatory Diarrhea. Ye Z, Kini A, Tan Q, et al. The Journal of Nutritional Biochemistry. 2025;138:109847. doi:10.1016/j.jnutbio.2025.109847.
37. In Vitro Digestion and Fermentation of Microencapsulated Tributyrin for the Delivery of Butyrate. Donovan JD, Bauer L, Fahey GC, Lee Y. Journal of Food Science. 2017;82(6):1491-1499. doi:10.1111/1750-3841.13725.
38. Tributyrin: A Prodrug of Butyric Acid for Potential Clinical Application in Differentiation Therapy. Chen ZX, Breitman TR. Cancer Research. 1994;54(13):3494-9.
39. Both Viable Bifidobacterium Longum Subsp. Infantis B8762 and Heat-Killed Cells Alleviate the Intestinal Inflammation of DSS-induced IBD Rats. Li Z, Peng C, Sun Y, et al. Microbiology Spectrum. 2024;12(6):e0350923. doi:10.1128/spectrum.03509-23.
40. The Viability of Lactobacillus Fermentum CECT5716 Is Not Essential to Exert Intestinal Anti-Inflammatory Properties. Rodríguez-Nogales A, Algieri F, Vezza T, et al. Food & Function. 2015;6(4):1176-84. doi:10.1039/c4fo00938j.
41. Live and Heat-Killed Lactobacillus Rhamnosus GG: Effects on Proinflammatory and Anti-Inflammatory Cytokines/Chemokines in Gastrostomy-Fed Infant Rats. Li N, Russell WM, Douglas-escobar M, et al. Pediatric Research. 2009;66(2):203-7. doi:10.1203/PDR.0b013e3181aabd4f.
42. Anti-Inflammatory Effects of Heat-Killed Lactiplantibacillus Argentoratensis BBLB001 on a Gut Inflammation Co-Culture Cell Model and Dextran Sulfate Sodium-Induced Colitis Mouse Model. Itoh T, Miyazono D, Sugata H, Mori C, Takahata M. International Immunopharmacology. 2024;143(Pt 2):113408. doi:10.1016/j.intimp.2024.113408.
43. Mechanism of TLR4-Mediated Anti-Inflammatory Response Induced by Exopolysaccharide From the Probiotic Bacillus Subtilis. Zamora-Pineda J, Kalinina O, Sperling AI, Knight KL. Journal of Immunology (Baltimore, Md. : 1950). 2023;211(8):1232-1239. doi:10.4049/jimmunol.2200855.
44. Interspecific Differences and Mechanisms of Lactobacillus-Derived Anti-Inflammatory Exopolysaccharides. Zhang J, Zhang H, Xiao Y, et al. International Journal of Biological Macromolecules. 2024;263(Pt 2):130313. doi:10.1016/j.ijbiomac.2024.130313.
45. Monosaccharide Composition Influence and Immunomodulatory Effects of Probiotic Exopolysaccharides. Chen YC, Wu YJ, Hu CY. International Journal of Biological Macromolecules. 2019;133:575-582. doi:10.1016/j.ijbiomac.2019.04.109.
46. Exopolysaccharides From Probiotic Bacteria and Their Health Potential. Angelin J, Kavitha M. International Journal of Biological Macromolecules. 2020;162:853-865. doi:10.1016/j.ijbiomac.2020.06.190.
47. Structural Characterization and in Vitro Anti-Inflammatory Activity of Exopolysaccharide Produced by Pediococcus Pentosaceus 4412. Angelin J, Kavitha M. International Immunopharmacology. 2025;150:114301. doi:10.1016/j.intimp.2025.114301.
48. Untargeted Metabolomics Reveals Shared and Unique Metabolites in Bifidobacterium and Lactobacillus Derived Postbiotics. Liu Y, Sun Y, Fang B, et al. Journal of Agricultural and Food Chemistry. 2025;. doi:10.1021/acs.jafc.5c10317.
49. Immunomodulating Activity and Therapeutic Effects of Short Chain Fatty Acids and Tryptophan Post-Biotics in Inflammatory Bowel Disease. Russo E, Giudici F, Fiorindi C, et al. Frontiers in Immunology. 2019;10:2754. doi:10.3389/fimmu.2019.02754.
50. JK5G Postbiotics Modulate Gut Microbiota and Metabolome to Alleviate Cancer-Related Pain: A Randomized Controlled Trial With Multi-Omics Integration. Chen M, Zhang J, Yang H, et al. Frontiers in Immunology. 2026;17:1764491. doi:10.3389/fimmu.2026.1764491.
51. L-Carnitine and Synbiotic Co-Supplementation: Beneficial Effects on Metabolic-Endotoxemia, Meta-Inflammation, and Oxidative-Stress Biomarkers in Obese Patients: A Double Blind, Randomized, Controlled Clinical Trial. Fallah F, Mahdavi R. Food & Function. 2023;14(4):2172-2187. doi:10.1039/d2fo03348h.
52. PRKN/parkin-mediated Mitophagy Is Induced by the Probiotics and . Hawrysh PJ, Gao J, Tan S, et al. Autophagy. 2023;19(7):2094-2110. doi:10.1080/15548627.2023.2172873.
53. Mechanistic Basis and Preliminary Practice of Butyric Acid and Butyrate Sodium to Mitigate Gut Inflammatory Diseases: A Comprehensive Review. Zhang M, Wang Y, Zhao X, et al. Nutrition Research (New York, N.Y.). 2021;95:1-18. doi:10.1016/j.nutres.2021.08.007.
54. Butyrate: A Double-Edged Sword for Health?. Liu H, Wang J, He T, et al. Advances in Nutrition (Bethesda, Md.). 2018;9(1):21-29. doi:10.1093/advances/nmx009.
55. High Doses of Butyrate Induce a Reversible Body Temperature Drop Through Transient Proton Leak in Mitochondria of Brain Neurons. Xu Y, Peng S, Cao X, et al. Life Sciences. 2021;278:119614. doi:10.1016/j.lfs.2021.119614.

Emphasis on Education

 

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

 

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

 

Should you wish more information regarding any of the subjects listed – or not listed –  here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

 

For more information, please contact Accurate Clinic.

 

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.

 

 

.